These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 597473)

  • 21. Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors.
    Berkelhammer J; Mastrangelo MJ; Laucius JF; Bodurtha AJ; Prehn RT
    Int J Cancer; 1975 Oct; 16(4):571-8. PubMed ID: 51835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active-specific immunotherapy for melanoma.
    Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
    J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
    Embleton MJ; Ransom JH; McIllmurray MB; Reeves WG
    Br J Cancer; 1978 Apr; 37(4):497-504. PubMed ID: 565645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [T-lymphocytes in the peripheral blood. Study on 113 patients with malignant melanoma].
    Klein R; Krüger GR; Sesterhenn K
    Z Hautkr; 1978 Feb; 53(3):62-6. PubMed ID: 305173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of diphenylhydantoin on killer cell activity and other immunological functions. A sequential study including the interaction of Corynebacterium parvum in melanoma patients.
    Thatcher N; Wan HH; Swindell R; Wilkinson PM; Crowther D
    Int J Immunopharmacol; 1982; 4(3):167-74. PubMed ID: 7107099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
    Newlands ES; Oon CJ; Roberts JT; Elliott P; Mould RF; Topham C; Madden FJ; Newton KA; Westbury G
    Br J Cancer; 1976 Aug; 34(2):174-9. PubMed ID: 962994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
    Currie GA; McElwain TJ
    Br J Cancer; 1975 Feb; 31(2):143-56. PubMed ID: 1164466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary evaluation of immunotherapy in patients with Hodgkin's disease.
    Zywicka-Lopaciuk H; Konopka L; Karpowicz M; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Małkowska-Zwierz W; Pawelski S
    Arch Immunol Ther Exp (Warsz); 1981; 29(6):739-55. PubMed ID: 7349093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of BCG immunotherapy on alloantigen-induced blastogenesis and cytotoxicity of lymph node lymphocytes in patients with melanoma.
    Callery CD; Morton DL; Golub SH
    Surg Forum; 1979; 30():152-4. PubMed ID: 161421
    [No Abstract]   [Full Text] [Related]  

  • 30. [Development in the immunotherapy of malignant melanoma].
    Tritsch H
    Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
    Knopf B; Wätzig V; Knöll B
    Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antitumor reactivity of mononuclear leukocytes from cancer patients receiving immunotherapy with BCG.
    Mavligit GM; Hersh EM
    Med Pediatr Oncol; 1978; 5(1):115-26. PubMed ID: 370532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Possibilities of immunotherapy in malignant melanoma].
    Lewis MG
    Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
    Mitchell MS; Mokyr MB; Davis JM
    J Clin Invest; 1977 Jun; 59(6):1017-26. PubMed ID: 863999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCG as active immunotherapy in children with acute lymphoblastic leukemia in longstanding remission: positive effects on remission duration and immunologic parameters.
    Miale TD; Yocum D; Yocum C
    Biomedicine; 1978 May; 28(2):96-104. PubMed ID: 276382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune response and non-specific immunotherapy in melanoma.
    El-Domeiri AA
    Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in patients with melanoma.
    Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
    Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma.
    Marshall JA; Forster TH; Purdie DM; Lanagan CM; O'Connor LE; O'Rourke MG; Johnson MK; See JL; Ellem KA; Martinez NR; López JA; Schmidt CW
    Immunol Cell Biol; 2006 Jun; 84(3):295-302. PubMed ID: 16681827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
    Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
    Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.